Category
Cancer
Sub Category
Myeloma
Study Name
E1A11: Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) versus Carflizomib, Lenalidomide and Dexamethasone (CRd) followed by limited or indefinite Duration Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Principal Investigator
Gordon Srkalovic, MD, PhD
Study Information
https://www.clinicaltrials.gov/ct2/show/NCT01863550?term=E1A11&rank=1
Contact for Questions
Nurse - Vicki 517-364-2811

Site view: at a glance